Arch Therapeutics Inc (ARTH) 0.6200 $ARTH
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
Marketwire Canada - Mon Aug 15, 5:57AM CDT
Clinical Safety and Performance of AC5 Successfully Demonstrated in Dermatology Procedure Performed on 46 Skin Lesion Patients With Bleeding Wounds
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
Marketwire Canada - Mon Jun 06, 6:57AM CDT
Data Expected During Summer 2016 After Completion of 30-Day Follow-Up and Subsequent Statistical Analysis
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
Marketwired - Fri May 27, 8:00AM CDT
FRAMINGHAM, MA--(Marketwired - May 27, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that it has entered into subscription agreements with a group of accredited investors (the "Investors" to purchase approximately $3.4 million of the Company's securities in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder (the "Private Placement".
Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
Marketwire Canada - Mon May 16, 6:57AM CDT
U.S. Patent Addresses Self-Assembling Peptidomimetics That Form Barrier Structures on Tissue and Inhibit or Prevent the Passage of Bodily Fluids and Contaminants
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
Marketwire Canada - Tue May 10, 6:57AM CDT
U.S. Patent Addresses Controlling the Movement of Bodily Fluids With Meshes That Include Self-Assembling Peptides
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
Marketwired - Tue May 03, 8:19PM CDT
U.S. Patent Addresses Use of the Self-Assembling Peptide Barrier Technology to Treat Disorders Involving Leaky Tight Junctions and Extracellular Matrix
Revenue up 354% in 3D Printing And Royalty Agreement with Fortune 500 Manufacturer - Other Stocks to Watch
ACCESSWIRE - Mon May 02, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / May 2, 2016 / EmergingGrowth.com - Graphene 3D Lab, Inc. (OTCQB: GPHBF) just released its quarterly report for the period ending February 29, 2016 showing an increase in revenue of 354% over their November 30, 2016 quarter.
TERP: 12.17 (+0.25), GS: 165.55 (+2.30), UPL: 0.31 (unch), HPQ: 14.52 (+0.24)
Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016
Marketwired - Tue Apr 26, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will present at PIONEERS 2016, hosted by Joseph Gunnar & Co., on Thursday, May 5, 2016 at 4:30 PM EDT.
Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides
Marketwired - Mon Apr 11, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced today that a notice of allowance from the U.S. Patent Office has been received on a broad method of use patent assigned to the Massachusetts Institute of Technology (MIT) and Versitech Limited, and which is exclusively licensed worldwide to Arch. The broad method claims of the patent cover techniques for preventing the loss or unwanted movement of body fluids, through the application of Arch's present and future potential products in development. These potential products contain peptides that self-assemble into barrier structures on tissue that inhibit or prevent the passage of bodily fluids. Examples of procedures supported by this intellectual property include the use of hemostatic agents to stop bleeding and use of sealants to stop leaks.
Pre-Market Alert - 4 Stocks That You Should Be Watching Today (4/7/2016)
ACCESSWIRE - Thu Apr 07, 8:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. MSTX, REXX, ARTH and TRTC are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
MSTX: 0.42 (+0.03), REXX: 0.62 (+0.05)
Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides
Marketwired - Tue Apr 05, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced today that a notice of allowance from the U.S. Patent Office has been received on a broad composition-of-matter patent that is assigned to the Massachusetts Institute of Technology (MIT) and Versitech Limited, and which is exclusively licensed worldwide to Arch. The broad composition claims of the patent cover Arch's present and proposed products, which contain peptides that self-assemble into barrier structures on tissue that inhibit or prevent the passage of bodily fluids. Examples of potential products supported by this intellectual property include hemostatic agents to stop bleeding and sealants to stop leaks.
Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans
Marketwired - Tue Mar 22, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company", developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)", reports favorable data from a 21-day repeat exposure skin test to evaluate the irritation potential of AC5 to human skin. This represents the first safety data obtained for AC5 from human testing.
Arch Therapeutics, Inc. (OTCQB: ARTH) Patient Enrollment and Treatment in First Clinical Trial in Western Europe
ACCESSWIRE - Mon Mar 14, 12:04PM CDT
FRAMINGHAM, MA / ACCESSWIRE / March 14, 2016 / Arch Therapeutics, Inc. (OTCQB: ARTH) a life science medical device company focused on developing an approach for the cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care, has recently announced that it has initiated patient enrollment and treatment in its first clinical trial in Western Europe. Terrence W. Norchi, MD, President and CEO of Arch, said, "The start of this trial marks a major milestone for the Company. It is firmly underway with patients being actively screened, enrolled, and treated or scheduled for treatment. Our team has put in tremendous effort to get us to this point and we are pleased with this progress."
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
Marketwire Canada - Mon Aug 15, 5:57AM CDT
Clinical Safety and Performance of AC5 Successfully Demonstrated in Dermatology Procedure Performed on 46 Skin Lesion Patients With Bleeding Wounds
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
Marketwire Canada - Mon Jun 06, 6:57AM CDT
Data Expected During Summer 2016 After Completion of 30-Day Follow-Up and Subsequent Statistical Analysis
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
Marketwired - Fri May 27, 8:00AM CDT
FRAMINGHAM, MA--(Marketwired - May 27, 2016) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device™ (AC5™) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, is pleased to announce that it has entered into subscription agreements with a group of accredited investors (the "Investors" to purchase approximately $3.4 million of the Company's securities in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder (the "Private Placement". Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
Marketwire Canada - Mon May 16, 6:57AM CDT
U.S. Patent Addresses Self-Assembling Peptidomimetics That Form Barrier Structures on Tissue and Inhibit or Prevent the Passage of Bodily Fluids and Contaminants
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
Marketwire Canada - Tue May 10, 6:57AM CDT
U.S. Patent Addresses Controlling the Movement of Bodily Fluids With Meshes That Include Self-Assembling Peptides
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
Marketwired - Tue May 03, 8:19PM CDT
U.S. Patent Addresses Use of the Self-Assembling Peptide Barrier Technology to Treat Disorders Involving Leaky Tight Junctions and Extracellular Matrix
Revenue up 354% in 3D Printing And Royalty Agreement with Fortune 500 Manufacturer - Other Stocks to Watch
ACCESSWIRE - Mon May 02, 7:30AM CDT
MIAMI, FL / ACCESSWIRE / May 2, 2016 / EmergingGrowth.com - Graphene 3D Lab, Inc. (OTCQB: GPHBF) just released its quarterly report for the period ending February 29, 2016 showing an increase in revenue of 354% over their November 30, 2016 quarter.
TERP: 12.17 (+0.25), GS: 165.55 (+2.30), UPL: 0.31 (unch), HPQ: 14.52 (+0.24)
Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016
Marketwired - Tue Apr 26, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, will present at PIONEERS 2016, hosted by Joseph Gunnar & Co., on Thursday, May 5, 2016 at 4:30 PM EDT. Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides
Marketwired - Mon Apr 11, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced today that a notice of allowance from the U.S. Patent Office has been received on a broad method of use patent assigned to the Massachusetts Institute of Technology (MIT) and Versitech Limited, and which is exclusively licensed worldwide to Arch. The broad method claims of the patent cover techniques for preventing the loss or unwanted movement of body fluids, through the application of Arch's present and future potential products in development. These potential products contain peptides that self-assemble into barrier structures on tissue that inhibit or prevent the passage of bodily fluids. Examples of procedures supported by this intellectual property include the use of hemostatic agents to stop bleeding and use of sealants to stop leaks. Pre-Market Alert - 4 Stocks That You Should Be Watching Today (4/7/2016)
ACCESSWIRE - Thu Apr 07, 8:08AM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. MSTX, REXX, ARTH and TRTC are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.
MSTX: 0.42 (+0.03), REXX: 0.62 (+0.05)
Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides
Marketwired - Tue Apr 05, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced today that a notice of allowance from the U.S. Patent Office has been received on a broad composition-of-matter patent that is assigned to the Massachusetts Institute of Technology (MIT) and Versitech Limited, and which is exclusively licensed worldwide to Arch. The broad composition claims of the patent cover Arch's present and proposed products, which contain peptides that self-assemble into barrier structures on tissue that inhibit or prevent the passage of bodily fluids. Examples of potential products supported by this intellectual property include hemostatic agents to stop bleeding and sealants to stop leaks. Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans
Marketwired - Tue Mar 22, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"
, developer of the AC5 Surgical Hemostatic Device(TM) ("AC5(TM)", reports favorable data from a 21-day repeat exposure skin test to evaluate the irritation potential of AC5 to human skin. This represents the first safety data obtained for AC5 from human testing. Arch Therapeutics, Inc. (OTCQB: ARTH) Patient Enrollment and Treatment in First Clinical Trial in Western Europe
ACCESSWIRE - Mon Mar 14, 12:04PM CDT
FRAMINGHAM, MA / ACCESSWIRE / March 14, 2016 / Arch Therapeutics, Inc. (OTCQB: ARTH) a life science medical device company focused on developing an approach for the cessation of bleeding (hemostasis) and control of fluid leakage (sealant) during surgery and trauma care, has recently announced that it has initiated patient enrollment and treatment in its first clinical trial in Western Europe. Terrence W. Norchi, MD, President and CEO of Arch, said, "The start of this trial marks a major milestone for the Company. It is firmly underway with patients being actively screened, enrolled, and treated or scheduled for treatment. Our team has put in tremendous effort to get us to this point and we are pleased with this progress."
